Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Oblique Therapeutics AB (publ)
AB
Active
Org 5590174487
Askim
Research and experimental development on natural sciences and engineering
· NACE 7210
Est. 2015
5-9 employees
Watchlist
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Oblique Therapeutics AB (publ)
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
0M
1M
1M
1M
0M
2020
0M
2021
0M
2022
0M
2023
0M
2024
EBITDA
SEK millions
0M
-8M
-16M
-24M
-32M
-28M
2020
-48M
2021
-46M
2022
-38M
2023
-29M
2024
Income statement
SEK thousands
Item
2020
2021
2022
2023
2024
Revenue
150
0
0
0
491
Staff expenses
—
—
—
—
—
EBITDA
−27 520
−48 175
−45 896
−37 765
−28 512
Depreciation & amort.
−458
−995
−1 065
−985
−940
EBIT
−27 978
−49 170
−46 961
−38 750
−29 452
Net financials
−3 545
−203
−64 748
−23 199
105
Profit before tax
−31 523
−49 373
−111 709
−61 929
−29 347
Tax
−0
−0
−0
−0
−0
Net profit
−31 523
−49 373
−111 709
−61 929
−29 347
Balance sheet
SEK thousands
Item
2020
2021
2022
2023
2024
Total assets
156 244
107 266
33 924
18 561
17 143
Equity
144 781
98 394
23 930
11 589
11 209
Long-term debt
850
850
850
850
850
Short-term debt
10 613
8 022
9 144
6 122
5 084
Total debt
11 463
8 872
9 994
6 972
5 934
Financial ratios
5-year trend
EBITDA margin
-5806.9%
This company
15.8%
Market median
-36853% vs market
2020
2024
Equity ratio
65.4%
This company
38.2%
Market median
+71% vs market
2020
2024
Return on equity
-261.8%
This company
18.4%
Market median
-1523% vs market
2020
2024
Net profit margin
-5977.0%
This company
8.1%
Market median
-73890% vs market
2020
2024
Asset turnover
0.03×
This company
1.12×
Market median
-97% vs market
2020
2024
Debt / equity
0.53×
This company
0.62×
Market median
+15% vs market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
View
PDF
More on Oblique Therapeutics AB (publ)
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
